Support Alert

Class 3 Medicines Recall: Lynparza 50mg capsules (olaparib)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 3 medicines recall for specific batches of Lynparza 50mg capsules (olaparib). AstraZeneca is recalling a number of batches because one batch has levels of olaparib polymorphic form L exceeding the registered specification limit. Additional batches are being recalled as a precautionary measure.


Further details of the alert, the affected batches, and action to take are available on the MHRA website.